髓过氧化物酶-463 G/A基因多态性与肺癌风险相关：一项纳入7420例病例和9132例对照的荟萃分析。

Myeloperoxidase -463 G/A polymorphism is associated with lung cancer risk: A meta-analysis with 7420 cases and 9132 controls.

作者信息

Zou Shengqiang, Pan Xin, Hua Changsong, Wu Min, He Bin, Chen Zhigang

机构信息

The Third People's Hospital of Zhenjiang Affiliated to Jiangsu University; School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China.

School of Medicine, Jiangsu University; Department of Medical Section, Zhenjiang Emergency Medical Center, Zhenjiang, Jiangsu, China.

出版信息

J Cancer Res Ther. 2018 Jun;14(Supplement):S282-S287. doi: 10.4103/0973-1482.235341.

DOI:10.4103/0973-1482.235341

PMID:29970677

Abstract

AIMS

Several studies evaluated the association between myeloperoxidase (MPO) -463 G/A polymorphism and the risk of lung cancer. However, the results were not stable.

MATERIALS AND METHODS

Online electronic databases (PubMed, EMBASE, and Wanfang database) were searched. The strength of association between the MPO -463 G/A polymorphism and lung cancer risk was assessed by calculating odds ratios (OR) with 95% confidence interval (CI).

RESULTS

A total of 22 studies with 7420 cases and 9132 controls on the association between MPO -463 G/A polymorphism and lung cancer risk were included for this meta-analysis. MPO -463 G/A polymorphism was associated with a significantly decreased risk of lung cancer (OR = 0.91; 95% CI: 0.85-0.98; I = 25%). In the race subgroup analysis, Asians with MPO -463 G/A polymorphism had decreased lung cancer risk (OR = 0.81; 95% CI: 0.70-0.93; I = 0%). However, Caucasians did not show significant result (OR = 0.93; 95% CI: 0.86-1.02; I = 36%). In the subgroup analysis according to source of control, both population-based studies and hospital-based studies were marginally significantly associated with decreased risk of lung cancer (OR = 0.90; 95% CI: 0.82-1.00; I = 41% and OR = 0.91; 95% CI: 0.82-1.01; I = 0%).

CONCLUSION

The present meta-analysis suggested that the MPO -463 G/A polymorphism carriers had a protective role in lung cancer.

摘要

目的

多项研究评估了髓过氧化物酶（MPO）-463 G/A多态性与肺癌风险之间的关联。然而，结果并不稳定。

材料与方法

检索在线电子数据库（PubMed、EMBASE和万方数据库）。通过计算比值比（OR）及95%置信区间（CI）评估MPO -463 G/A多态性与肺癌风险之间的关联强度。

结果

本荟萃分析纳入了22项研究，共7420例病例和9132例对照，研究MPO -463 G/A多态性与肺癌风险之间的关联。MPO -463 G/A多态性与肺癌风险显著降低相关（OR = 0.91；95% CI：0.85 - 0.98；I² = 25%）。在种族亚组分析中，具有MPO -463 G/A多态性的亚洲人肺癌风险降低（OR = 0.81；95% CI：0.70 - 0.93；I² = 0%）。然而，高加索人未显示出显著结果（OR = 0.93；95% CI：0.86 - 1.02；I² = 36%）。在根据对照来源进行的亚组分析中，基于人群的研究和基于医院的研究均与肺癌风险降低存在边缘显著关联（OR = 0.90；95% CI：0.82 - 1.00；I² = 41%和OR = 0.91；95% CI：0.82 - 1.01；I² = 0%）。